CNS Pharmaceuticals Inc. (CNSP)
| Bid | 1.08 |
| Market Cap | 3.33M |
| Revenue (ttm) | 1.57K |
| Net Income (ttm) | -14.86M |
| EPS (ttm) | -1943.5 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.24 |
| Analyst | Buy |
| Ask | 1.17 |
| Volume | 95,569 |
| Avg. Volume (20D) | 522,409 |
| Open | 1.07 |
| Previous Close | 1.06 |
| Day's Range | 1.05 - 1.15 |
| 52-Week Range | 0.77 - 800.00 |
| Beta | 1.08 |
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson...
Analyst Forecast
According to 1 analyst ratings, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 2112.39% from the latest price.
Stock Forecasts
2 months ago · accessnewswire.com
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ ListingCash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopha...
2 months ago · accessnewswire.com
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO ForumWebcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical c...
2 months ago · accessnewswire.com
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceOn-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializin...
2 months ago · accessnewswire.com
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development SummitHOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo...
2 months ago · accessnewswire.com
CNS Pharmaceuticals to Present at the BIO CEO & Investor ConferenceIn-person presentation today, February 10th at 1:15 PM ET HOUSTON, TX / ACCESS Newswire / February 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical co...